For Immediate Release
Chicago, IL – October 13, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Emergent BioSolutions Inc.
EBS
, Vertex Pharmaceuticals Incorporated
VRTX
, Editas Medicine, Inc.
EDIT
, Cellectis S.A.
CLLS
and Thermo Fisher Scientific Inc.
TMO
.
Here are highlights from Monday’s Analyst Blog:
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
The biotech space has been booming in the past decade, with areas like gene editing stealing the show as they increase scope for treating life-threatening diseases. Gene editing or genome engineering is a process in which a DNA is inserted, modified or replaced in the genome of any living organism. In recent years, scientists have been using gene editing technology to help treat diseases with a genomic basis, like cystic fibrosis, diabetes and cancer.
CRISPR or “Clustered Regularly Interspaced Short Palindromic Repeats” is a tool primarily used to edit genes at present. Many scientists believe that this year could be a breakthrough in finding cures for cancer in DNA and investors could get familiar with terms like CRISPR and precision medicine to make the most out of advancements in this space.
Additionally, the coronavirus outbreak has pushed scientists to look for a cure through gene editing, as this novel virus keeps wreaking havoc and claiming millions of lives globally.
Disruptive Biotech Making a Mark in 2020
Cancer has been the second-leading cause of death in the United States over the past few years. Per Centers for Disease Control and Prevention (CDC)
data
, nearly 599,108 people lost their lives due to cancer in 2019. Gene editing has now opened up ways in which alterations in the DNA will allow patients to train their body to destroy life-threatening tumors.
Additionally, utilization of order writing techniques to rewrite infected cells and tissues, and removal of harmful mutations are also expected to boost this space. Several biotech firms are now using immuno-oncology treatments in which the immuno-oncology class of drugs teach or direct the immune system to identify cancer and then destroy it. In fact, techniques like correction within the harmful mutations, disruption of infectious agent in the DNA, or the addition of therapeutic transgenes are boosting the gene editing market.
According to
Emergen Research
report, the global gene editing market is projected to reach $15.79 billion by 2027 from $4.44 billion in 2019, at a CAGR of 17.2%.
One of the recent gene editing tools worth mentioning is the PAC-MAN or Prophylactic Antiviral CRISPR in human cells tool. Stanford University scientists have developed an antiviral agent against the novel coronavirus that can target and destroy specific genetic strands of the virus inside the human cell itself. The PAC-MAN which is composed of an enzyme and a strand of guide RNA has provided promising results in the laboratory when tested on human lung cells infected with SARS-CoV-2.
2020 Nobel Prize Award Boosts the Space
2020 has been a banner year for the gene editing space so far, with several treatments, techniques and drugs in the pipeline. The gene editing space is now in the limelight after Jennifer Doudna, PhD, and Emmanuelle Charpentier, PhD, pioneers in the development of CRISPR technology as “genetic scissors,” have been announced as 2020 Nobel Prize winners for Chemistry.
The CRISPR-Cas9 “genetic scissors” technology was discovered in 2012 and has won several scientific awards and recognitions in the past years, lending an additional boost to the gene editing space. The news of the award helped major gene editing stocks like CRISPR Therapeutics rise 11.4% on Oct 7, as Charpentier is one of the co-founders of the company.
A team of researchers led by Doudna recently developed a unique test that can detect the coronavirus infection in just five minutes. The test uses gene editing technology and a modified mobile phone camera to detect the level of virus infection in a person. The test requires a mobile phone camera and a portable device with low-cost laser illumination and collection optics. Though the test is still in pre-print, it can be easily commercialized and people could receive immediate coronavirus tests even at their home, once it’s successful.
What’s more? Costs in the gene editing space have gone down steeply in the past few years, making the genetic investigation process more affordable. Research shows that 30 years ago, the cost to read the entire DNA in a single human being was nearly $3 billion, which at present stands at around $1,000 and may fall to $100 in the future.
5 Top Choices
The advancements in gene editing and its potential for growth could help biotech stocks grow leaps and bounds in the future. Here, we have shortlisted five stocks that can make the most of this boom.
Emergent BioSolutions
is a life sciences company that focuses on the provision of specialty products to the civilian and military population that addresses accidental, deliberate, and naturally-occurring public health threats. The company’s expected earnings growth rate for the current year is more than 100% compared with the Zacks
Medical – Biomedical and Genetics
industry’s projected earnings growth of 13.8%.
The Zacks Consensus Estimate for this Zacks Rank #1 (Strong Buy) company’s current-year earnings has been revised 64% upward over the past 90 days. You can see
the complete list of today’s Zacks #1 Rank stocks here
.
Vertex Pharmaceuticals
engages in developing and commercializing therapies for treating cystic fibrosis. The company that belongs to the Medical – Biomedical and Genetics industry has an expected earnings growth rate of 82.4% for the current year. The Zacks Consensus Estimate for this Zacks Rank #2 (Buy) company’s current-year earnings has been raised 9.3% over the past 90 days.
Editas Medicine
operates as a clinical stage genome editing company. The company that belongs to the Medical – Biomedical and Genetics industry has an expected earnings growth rate of 0.4%for the current year. The Zacks Consensus Estimate for this Zacks Rank #2 company’s current-year earnings has risen 13.5% over the past 90 days.
Cellectis
is a clinical stage biotechnological company that develops immuno-oncology products based on gene-edited T-cells. The company that belongs to Medical – Biomedical and Genetics industry has an expected earnings growth rate of 88.6% in the next quarter. The Zacks Consensus Estimate for this Zacks Rank #2 company’s current-year earnings has moved up 18.1% over the past 60 days.
Thermo Fisher Scientific
provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services. The company’s expected earnings growth rate for the current year is 28.4% compared with the Zacks
Medical – Instruments
industry’s projected earnings growth of 5.9%. The Zacks Consensus Estimate for this Zacks Rank #2 company’s current-year earnings has been revised 6% upward over the past 60 days.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Check out the 2020 Election Stock Report >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
